Review article: Nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 1, 2014, Pages 35-46

  Pipili, C ^a   Cholongitas, E ^b   Papatheodoridis, G ^c  

^a Laiki Merimna ^*  (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; IMMUNOGLOBULIN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ESTIMATED GLOMERULUS FILTRATION RATE; FANCONI RENOTUBULAR SYNDROME; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; NEPHROTOXICITY; ORGAN DONOR; OSTEOMALACIA; PATIENT MONITORING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIREMIA; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; ORGANOPHOSPHONATES; RENAL INSUFFICIENCY, CHRONIC; THYMIDINE;

EID: 84889687049     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12538     Document Type: Article

References (115)

1. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
2. Papatheodoridis GV,. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 2013; 33 (Suppl. 1): 151-6.
3. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ,. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-78.
5. Papatheodoridis GV, Dimou E, Papadimitropoulos V,. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618-28.
6. Chang TT, Gish RG, de Man R, et al,. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
7. Dienstag JL, Schiff ER, Wright TL, et al,. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
8. Lai CL, Gane E, Liaw YF, et al,. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
9. Lai CL, Shouval D, Lok AS, et al,. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
10. Tassopoulos NC, Volpes R, Pastore G, et al,. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
11. Lok AS, Lai CL, Leung N, et al,. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
12. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ,. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
14. Marcellin P, Chang TT, Lim SG, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
15. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
16. Peters MG, Hann HW, Martin P, et al,. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
17. Papatheodoridis GV, Hadziyannis SJ,. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19: 25-37.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
19. Liaw YF, Gane E, Leung N, et al,. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
20. Gane EJ, Deray G, Piratvisuth T, et al,. Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine. Hepatology 2011; 54 (Suppl.): 1044A.
21. Wang Y, Thongsawat S, Gane EJ, et al,. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013; 20: e37-46.
22. Chang TT, Lai CL, Kew Yoon S, et al,. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
23. Tenney DJ, Rose RE, Baldick CJ, et al,. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
24. Heathcote EJ, Marcellin P, Buti M, et al,. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
25. Marcellin P, Buti M, Gane EJ, et al,. Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013; 56 (Suppl.): 374A-5A.
26. Lampertico P, Soffredini R, Vigano M, et al,. Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naïve patients with chronic hepatitis B followed for 3 years in a multicenter European study. Hepatology 2012; 56 (Suppl): 389A.
27. van Bommel F, de Man RA, Wedemeyer H, et al,. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
28. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S,. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 941-6.
29. Mauss S, Berger F, Filmann N, et al,. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: 1235-40.
30. Chan HL, Chen YC, Gane EJ, et al,. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-43.
31. Piratvisuth T, Komolmit P, Tanwandee T, et al,. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS ONE 2013; 8: e54279.
32. Amarapurkar DN, Patel N,. Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection. Indian J Gastroenterol 2013 [Epub ahead of print].
33. Cihlar T, Ho ES, Lin DC, Mulato AS,. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides Nucleic Acids 2001; 20: 641-8.
34. Hadziyannis SJ, Papatheodoridis GV,. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004; 2: 475-83.
35. Perazella MA,. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325: 349-62.
36. Ha NB, Garcia RT, Trinh HN, et al,. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-34.
37. Durante-Mangoni E, Iossa D, Pinto D, et al,. Adefovir treatment for chronic hepatitis B in heart transplant recipients. Clin Transplant 2013; 27: E282-8.
38. Gara N, Zhao X, Collins MT, et al,. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317-25.
39. Del Palacio M, Romero S, Casado JL,. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012; 14: 179-87.
40. Hall AM, Hendry BM, Nitsch D, Connolly JO,. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80.
41. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G,. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-90.
42. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al,. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
43. Girgis CM, Wong T, Ngu MC, et al,. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011; 45: 468-73.
44. Manolakopoulos S, Striki A, Deutsch M, et al,. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int 2011; 31: 1525-32.
45. Marcellin P, Buti M, Gane EJ, et al,. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54 (Suppl.): 1011A.
46. Izzedine H, Hulot JS, Vittecoq D, et al,. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-6.
47. Laprise C, Baril JG, Dufresne S, Trottier H,. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis 2013; 56: 567-75.
48. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E,. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-87.
49. Guillevin L, Mahr A, Callard P, et al,. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-22.
50. Bhimma R, Coovadia HM,. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198-211.
51. Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LT,. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol 2003; 9: 2004-8.
52. Herberth J, Herberth Z, Abul-Ezz SR, Kumar J, Gokden N,. Hepatitis B infection as a possible cause of focal segmental glomerulosclerosis (FSGS). Clin Nephrol 2006; 65: 380-4.
53. Chuang TW, Hung CH, Huang SC, Lee CM,. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc 2007; 106: 869-73.
54. Gan SI, Devlin SM, Scott-Douglas NW, Burak KW,. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection. Can J Gastroenterol 2005; 19: 625-9.
55. Mesquita M, Lasser L, Langlet P,. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol 2008; 70: 69-71.
56. Okuse C, Yotsuyanagi H, Yamada N, et al,. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. Clin Nephrol 2006; 65: 53-6.
57. Panomsak S, Lewsuwan S, Eiam-Ong S, Kanjanabuch T,. Hepatitis-B virus-associated nephropathies in adults: a clinical study in Thailand. J Med Assoc Thai 2006; 89 (Suppl. 2): S151-6.
58. Sakallioglu O, Gok F, Kalman S, Kurekci AE, Gunhan O, Gokcay E,. Hepatitis B complicated focal segmental glomerulosclerosis. J Nephrol 2005; 18: 433-5.
59. Sun IO, Hong YA, Park HS, et al,. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 2012; 27: 411-6.
60. Tang S, Lai FM, Lui YH, et al,. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-8.
61. Wen YK, Chen ML,. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 2006; 65: 211-5.
62. Ikee R, Ishioka K, Oka M, et al,. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology (Carlton) 2010; 15: 266.
63. Liu ZH, Yuan F,. Entecavir combined steroid therapy of clinical manifestations of nephrotic syndrome in HBV-GN. J Clin Res 2008; 11: 2264-6.
64. Sakai K, Morito N, Usui J, et al,. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. Nephrol Dial Transplant 2011; 26: 371-3.
65. Yang YF, Xiong QF, Zhao W, Zhong YD,. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clin Res Hepatol Gastroenterol 2012; 36: e89-92.
66. Yan Z, Li S, Liu Y, Wang Z, Jia D,. Telbivudine treatment of chronic hepatitis B patients complicated with hepatitis B virus associated glomerulonephritis. APASL 2013;Abstr. A-535.
67. Yi Z, Jie YW, Nan Z,. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol 2011; 10: 165-73.
68. Zheng XY, Wei RB, Tang L, Li P, Zheng XD,. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18: 821-32.
69. Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P,. Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs 2008; 31: 386-94.
70. Fabrizi F, Messa P, Martin P,. Hepatitis B virus infection and the dialysis patient. Semin Dial 2008; 21: 440-6.
71. Crosnier J, Jungers P, Courouce AM, et al,. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1981; 1: 797-800.
72. Nagafuchi S, Kashiwagi S, Okada K, et al,. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991; 265: 2679-83.
73. Pol S, Nalpas B, Legendre C, Kreis H,. Effects of interleukin-2 on hepatitis B vaccination in uraemic patients. Lancet 1994; 344: 1369.
74. Lok AS,. Navigating the maze of hepatitis B treatments. Gastroenterology 2007; 132: 1586-94.
75. Marzano A, Angelucci E, Andreone P, et al,. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
76. KDIGO. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 109: S1-99.
77. Ahmad A, Hasan F, Abdeen S, et al,. Transjugular liver biopsy in patients with end-stage renal disease. J Vasc Interv Radiol 2004; 15: 257-60.
78. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group., Kasiske BL, Zeier MG, Craig JC, et al,. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-155.
79. Johnson MA, Verpooten GA, Daniel MJ, et al,. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998; 46: 21-7.
80. Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF,. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet 2006; 45: 1115-24.
81. Shiffman ML, Pol S, Rostaing L, et al,. Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment. J Clin Pharmacol 2011; 51: 1293-301.
82. Asari A, Iles-Smith H, Chen YC, et al,. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol 2007; 64: 738-44.
83. Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R,. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000; 95: 3579-83.
84. Boyacioglu S, Gur G, Gursoy M, Ozdemir N,. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant Proc 2002; 34: 2131-2.
85. Fontaine H, Thiers V, Chretien Y, et al,. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090-4.
86. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O,. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11: 400-2.
87. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z,. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003; 37: 64-7.
88. Fontaine H, Vallet-Pichard A, Chaix ML, et al,. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-92.
89. Gornals JB, Casanovas T, Sabido M, et al,. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. Transplant Proc 2005; 37: 3957-9.
90. Tillmann HL, Bock CT, Bleck JS, et al,. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003; 9: 191-6.
91. Ridruejo E, Adrover R, Alonso C, Mandõ OG, Silva MO,. Entecavir in the treatment of chronic hepatitis B in end stage renal disease and kidney transplantation. Dial Transplant 2010; 39: 397-400.
92. Izzedine H, Launay-Vacher V, Jullien V, Aymard G, Duvivier C, Deray G,. Pharmacokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant 2003; 18: 1931-3.
93. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G,. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-21.
94. Fornairon S, Pol S, Legendre C, et al,. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-9.
95. Santos L, Alves R, Macario F, Parada B, Campos M, Mota A,. Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience. Transplant Proc 2009; 41: 880-2.
96. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK,. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-52.
97. Pham PT, Pham PA, Pham PC, Parikh S, Danovitch G,. Evaluation of adult kidney transplant candidates. Semin Dial 2010; 23: 595-605.
98. Baid S, Tolkoff-Rubin N, Saidman S, et al,. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-8.
99. Fabrizi F, Bunnapradist S, Martin P,. Kidney transplantation and liver disease. In:, Danovitch G, ed. Handbook of Kidney Transplantation, 5th ed. Philadelphia: Lippincot Williams and Wilkins, 2010; 280-90.
100. Numata A, Akimoto T, Toshima M, et al,. Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection. Clin Exp Nephrol 2011; 15: 769-73.
101. Olsen SK, Brown RS Jr,. Hepatitis B treatment: lessons for the nephrologist. Kidney Int 2006; 70: 1897-904.
102. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P,. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-64.
103. Kamar N, Huart A, Tack I, Alric L, Izopet J, Rostaing L,. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009; 71: 36-42.
104. de Silva HJ, Dassanayake AS, Manamperi A, de Silva AP,. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006; 38: 3118-20.
105. Garcia A, Mazuecos A, Gonzalez P, et al,. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005; 37: 1462-3.
106. Tse KC, Yap DY, Tang CS, Yung S, Chan TM,. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010; 24: 207-12.
107. Lampertico P, Vigano M, Facchetti F, et al,. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011; 26: 2037-41.
108. Kamar N, Milioto O, Alric L, et al,. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-4.
109. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM,. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-30.
110. Daude M, Rostaing L, Saune K, et al,. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: 916-20.
111. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS,. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005; 19: 364-6.
112. De Feo TM, Grossi P, Poli F, et al,. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006; 81: 76-80.
113. Veroux M, Puliatti C, Gagliano M, et al,. Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and-negative recipients. Transplant Proc 2005; 37: 2574-5.
114. Jiang H, Wu J, Zhang X, et al,. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-8.
115. Berber I, Aydin C, Yigit B, Turkmen F, Titiz IM, Altaca G,. The effect of HBsAg-positivity of kidney donors on long-term patient and graft outcome. Transplant Proc 2005; 37: 4173-5.